CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
CAMK2N1 (CaMKIINα)
DNA methylation
Epithelial ovarian cancer
Prognostic marker
RUNX3
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
22 01 2021
22 01 2021
Historique:
received:
30
07
2020
accepted:
05
01
2021
entrez:
23
1
2021
pubmed:
24
1
2021
medline:
15
12
2021
Statut:
epublish
Résumé
To date, no predictive or prognostic molecular biomarkers except BRCA mutations are clinically established for epithelial ovarian cancer (EOC) despite being the deadliest gynecological malignancy. Aim of this biomarker study was the analysis of DNA methylation biomarkers for their prognostic value independent from clinical variables in a heterogeneous cohort of 203 EOC patients from two university medical centers. The marker combination CAMK2N1/RUNX3 exhibited a significant prognostic value for progression-free (PFS) and overall survival (OS) of sporadic platinum-sensitive EOC (n = 188) both in univariate Kaplan-Meier (LogRank p < 0.05) and multivariate Cox regression analysis (p < 0.05; hazard ratio HR = 1.587). KRT86 methylation showed a prognostic value only in univariate analysis because of an association with FIGO staging (Fisher's exact test p < 0.01). Thus, it may represent a marker for EOC staging. Dichotomous prognostic values were observed for KATNAL2 methylation depending on BRCA aberrations. KATNAL2 methylation exhibited a negative prognostic value for PFS in sporadic EOC patients without BRCA1 methylation (HR 1.591, p = 0.012) but positive prognostic value in sporadic EOC with BRCA1 methylation (HR 0.332, p = 0.04) or BRCA-mutated EOC (HR 0.620, n.s.). The retrospective analysis of 188 sporadic platinum-sensitive EOC proved an independent prognostic value of the methylation marker combination CAMK2N1/RUNX3 for PFS and OS. If validated prospectively this combination may identify EOC patients with worse prognosis after standard therapy potentially benefiting from intensive follow-up, maintenance therapies or inclusion in therapeutic studies. The dichotomous prognostic value of KATNAL2 should be validated in larger sample sets of EOC.
Sections du résumé
BACKGROUND
To date, no predictive or prognostic molecular biomarkers except BRCA mutations are clinically established for epithelial ovarian cancer (EOC) despite being the deadliest gynecological malignancy. Aim of this biomarker study was the analysis of DNA methylation biomarkers for their prognostic value independent from clinical variables in a heterogeneous cohort of 203 EOC patients from two university medical centers.
RESULTS
The marker combination CAMK2N1/RUNX3 exhibited a significant prognostic value for progression-free (PFS) and overall survival (OS) of sporadic platinum-sensitive EOC (n = 188) both in univariate Kaplan-Meier (LogRank p < 0.05) and multivariate Cox regression analysis (p < 0.05; hazard ratio HR = 1.587). KRT86 methylation showed a prognostic value only in univariate analysis because of an association with FIGO staging (Fisher's exact test p < 0.01). Thus, it may represent a marker for EOC staging. Dichotomous prognostic values were observed for KATNAL2 methylation depending on BRCA aberrations. KATNAL2 methylation exhibited a negative prognostic value for PFS in sporadic EOC patients without BRCA1 methylation (HR 1.591, p = 0.012) but positive prognostic value in sporadic EOC with BRCA1 methylation (HR 0.332, p = 0.04) or BRCA-mutated EOC (HR 0.620, n.s.).
CONCLUSION
The retrospective analysis of 188 sporadic platinum-sensitive EOC proved an independent prognostic value of the methylation marker combination CAMK2N1/RUNX3 for PFS and OS. If validated prospectively this combination may identify EOC patients with worse prognosis after standard therapy potentially benefiting from intensive follow-up, maintenance therapies or inclusion in therapeutic studies. The dichotomous prognostic value of KATNAL2 should be validated in larger sample sets of EOC.
Identifiants
pubmed: 33482905
doi: 10.1186/s13148-021-01006-8
pii: 10.1186/s13148-021-01006-8
pmc: PMC7824928
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Références
FEBS J. 2020 May;287(9):1700-1721
pubmed: 32027459
PLoS Biol. 2011 Nov;9(11):e1001199
pubmed: 22110403
Clin Exp Metastasis. 2006;23(1):65-74
pubmed: 16826427
J Med Genet. 2019 Sep;56(9):574-580
pubmed: 30979843
Cell Physiol Biochem. 2018;49(4):1329-1341
pubmed: 30205384
Ann Oncol. 2020 Sep;31(9):1240-1250
pubmed: 32473302
Genes Dis. 2018 Jan 31;5(1):1-8
pubmed: 30258928
Int J Cancer. 2017 Oct 15;141(8):1600-1614
pubmed: 28670762
Cancer Res. 2008 Feb 15;68(4):998-1002
pubmed: 18281473
Int J Gynecol Cancer. 2011 Feb;21(2):269-79
pubmed: 21270610
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
Acta Obstet Gynecol Scand. 2019 Jan;98(1):34-43
pubmed: 30168853
Semin Cancer Biol. 2018 Aug;51:160-169
pubmed: 28782606
Eur J Cancer. 2009 Feb;45(3):335-46
pubmed: 19138839
Oncol Rep. 2013 Sep;30(3):1019-29
pubmed: 23779253
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
pubmed: 11577478
Epigenetics. 2012 Nov;7(11):1268-78
pubmed: 23018867
Cancer Med. 2019 Nov;8(15):6756-6767
pubmed: 31503422
Trends Cell Biol. 2021 Jan;31(1):50-61
pubmed: 33183955
J Natl Cancer Inst. 2013 Jan 16;105(2):141-8
pubmed: 23257159
Gynecol Oncol. 2008 Apr;109(1):129-39
pubmed: 18234305
Cell Mol Life Sci. 2016 Jan;73(1):163-84
pubmed: 26153462
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Cancers (Basel). 2019 Mar 13;11(3):
pubmed: 30871186
JAMA. 2012 Jan 25;307(4):382-90
pubmed: 22274685
J Biol Chem. 2008 Apr 25;283(17):11565-74
pubmed: 18305109
Nat Cell Biol. 2010 May;12(5):492-9
pubmed: 20364141
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cancer Res. 2004 Sep 15;64(18):6476-81
pubmed: 15374957
Cancers (Basel). 2018 Apr 01;10(4):
pubmed: 29614786
Hum Cell. 2019 Oct;32(4):529-539
pubmed: 31452083
J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203
pubmed: 32413141
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
Ann Oncol. 2012 Oct;23(10):2605-2612
pubmed: 22910840
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cancer Lett. 2020 Mar 31;473:139-147
pubmed: 31904484
Oncotarget. 2017 Sep 15;8(47):83063-83074
pubmed: 29137324
Eur J Cancer. 2014 Aug;50(12):2090-8
pubmed: 24889916
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Clin Cancer Res. 2006 Nov 1;12(21):6386-94
pubmed: 17085650
Clin Cancer Res. 2009 Feb 15;15(4):1417-27
pubmed: 19193619
Oncogene. 1999 Apr 8;18(14):2335-41
pubmed: 10327053
J Oncol. 2019 Aug 5;2019:1232434
pubmed: 31467531
Mol Cancer. 2019 May 23;18(1):99
pubmed: 31122259
Front Genet. 2019 Jun 28;10:621
pubmed: 31316555
Clin Cancer Res. 2004 Jul 1;10(13):4420-6
pubmed: 15240532
Cancer Lett. 2020 Jan 1;468:59-71
pubmed: 31610267
CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92
pubmed: 20959400
Cancers (Basel). 2020 Oct 30;12(11):
pubmed: 33143170
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
Int J Cancer. 2016 Jan 1;138(1):217-28
pubmed: 26175272
Cancer Discov. 2018 Nov;8(11):1404-1421
pubmed: 30213835
Cancers (Basel). 2019 Jun 04;11(6):
pubmed: 31167492
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94
pubmed: 24218601
Int J Gynecol Cancer. 2011 Nov;21(8):1399-406
pubmed: 21897273
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Gynecol Oncol. 2014 Jun;133(3):624-31
pubmed: 24607285
Cancer Res. 2000 Oct 1;60(19):5329-33
pubmed: 11034065
Mol Oncol. 2009 Apr;3(2):97-137
pubmed: 19383374
Nat Rev Cancer. 2015 Feb;15(2):81-95
pubmed: 25592647
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Cancers (Basel). 2018 Sep 01;10(9):
pubmed: 30200478
Oncotarget. 2014 Jun 15;5(11):3611-21
pubmed: 25003983
Gynecol Oncol. 2016 May;141(2):379-385
pubmed: 26827964
Nat Rev Clin Oncol. 2018 Jul;15(7):459-466
pubmed: 29666440
Mol Oncol. 2015 May;9(5):960-6
pubmed: 25458054
Cell. 2015 Jun 4;161(6):1345-60
pubmed: 26004068
Int J Mol Sci. 2018 Jan 15;19(1):
pubmed: 29342962
Mol Med Rep. 2018 Aug;18(2):1812-1819
pubmed: 29845298
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
BMC Cancer. 2018 Apr 18;18(1):443
pubmed: 29669528
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
PLoS One. 2017 Oct 20;12(10):e0186043
pubmed: 29053726
Br J Cancer. 2001 Nov 2;85(9):1351-8
pubmed: 11720474
Clin Cancer Res. 2014 Mar 15;20(6):1513-20
pubmed: 24449826
Mol Diagn Ther. 2017 Feb;21(1):59-73
pubmed: 27718164
Mol Med Rep. 2019 Oct;20(4):3755-3763
pubmed: 31485638
Biomed Res Int. 2013;2013:852839
pubmed: 24063014
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Int J Mol Sci. 2013 Jul 10;14(7):14321-32
pubmed: 23846726